Stay updated with breaking news from Target Development Profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
IOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces that the innovative medicine designation, the Innovation Passport, has been awarded for roginolisib, for the...
/PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with...
Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema - read this article along with other careers information, tips and advice on BioSpace
Innovative Licensing and Access Pathway (ILAP) for medicines Guidance for applicants on applying to the ILAP From: Details The Innovative Licensing and Access Pathway (ILAP) aims to accelerate the time to market, facilitating patient access to medicines. These medicines include new chemical entities, biological medicines, new indications and repurposed medicines. The ILAP awards a new “innovative medicine” designation (Innovation Passport), utilises tools from a toolkit and a “Road Map” (Target Development Profile, TDP). The pathway brings together innovative approaches to support...